{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:10:12Z","timestamp":1791382212622,"version":"4.3.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11060-025-05100-2","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T09:45:19Z","timestamp":1749548719000},"page":"699-708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Whole Body-MRI assessment of peripheral lesions in patients with NF2-related schwannomatosis on systemic bevacizumab"],"prefix":"10.1007","volume":"174","author":[{"given":"Shivani","family":"Ahlawat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Debs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"5100_CR1","doi-asserted-by":"crossref","unstructured":"Plotkin S (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 1530\u20130366","DOI":"10.1212\/WNL.98.18_supplement.3996"},{"key":"5100_CR2","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Ye X, Duda DG et al (2016) Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-Associated vestibular schwannomas. J Clin Oncol 34:1669\u20131675. https:\/\/doi.org\/10.1200\/JCO.2015.64.3817","journal-title":"J Clin Oncol"},{"key":"5100_CR3","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMoa2400985","volume":"390","author":"SR Plotkin","year":"2024","unstructured":"Plotkin SR, Yohay KH, Nghiemphu PL et al (2024) Brigatinib in NF2-Related schwannomatosis with progressive tumors. N Engl J Med 390:2284\u20132294. https:\/\/doi.org\/10.1056\/NEJMoa2400985","journal-title":"N Engl J Med"},{"key":"5100_CR4","doi-asserted-by":"publisher","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","volume":"8","author":"F Nunez","year":"2013","unstructured":"Nunez F et al (2013) Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS ONE 8:e59941","journal-title":"PLoS ONE"},{"key":"5100_CR5","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"S Plotkin","year":"2012","unstructured":"Plotkin S et al (2012) Bevacizumab for progressive vestibular Schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33:1046\u20131052","journal-title":"Otol Neurotol"},{"key":"5100_CR6","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","volume":"37","author":"SR Plotkin","year":"2019","unstructured":"Plotkin SR, Duda DG, Muzikansky A et al (2019) Multicenter, prospective, phase II and biomarker study of High-Dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular Schwannoma. J Clin Oncol 37:3446\u20133454. https:\/\/doi.org\/10.1200\/JCO.19.01367","journal-title":"J Clin Oncol"},{"key":"5100_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jmri.24285","volume":"38","author":"R Attariwala","year":"2013","unstructured":"Attariwala R, Picker W (2013) Whole body MRI: improved lesion detection and characterization with diffusion weighted techniques. J Magn Reson Imaging 38:253\u2013268. https:\/\/doi.org\/10.1002\/jmri.24285","journal-title":"J Magn Reson Imaging"},{"key":"5100_CR8","doi-asserted-by":"publisher","unstructured":"Fayad LM, Blakeley J, Plotkin S et al (2013) Whole body MRI at 3T with quantitative diffusion weighted imaging and Contrast-Enhanced sequences for the characterization of peripheral lesions in patients with neurofibromatosis type 2 and schwannomatosis. ISRN Radiol 2013(627932). https:\/\/doi.org\/10.5402\/2013\/627932","DOI":"10.5402\/2013\/627932"},{"key":"5100_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1148\/radiol.2503080700","volume":"250","author":"W Cai","year":"2009","unstructured":"Cai W, Kassarjian A, Bredella MA et al (2009) Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology 250:665\u2013673. https:\/\/doi.org\/10.1148\/radiol.2503080700","journal-title":"Radiology"},{"key":"5100_CR10","doi-asserted-by":"publisher","first-page":"e35711","DOI":"10.1371\/journal.pone.0035711","volume":"7","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Bredella MA, Cai W et al (2012) Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS ONE 7:e35711. https:\/\/doi.org\/10.1371\/journal.pone.0035711","journal-title":"PLoS ONE"},{"key":"5100_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-013-1293-1","volume":"116","author":"R Nguyen","year":"2014","unstructured":"Nguyen R, Jett K, Harris GJ et al (2014) Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. J Neurooncol 116:307\u2013313. https:\/\/doi.org\/10.1007\/s11060-013-1293-1","journal-title":"J Neurooncol"},{"key":"5100_CR12","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1097\/RLU.0b013e3182a757d3","volume":"39","author":"T Urban","year":"2014","unstructured":"Urban T, Lim R, Merker VL et al (2014) Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion. Clin Nucl Med 39:e301\u2013e307. https:\/\/doi.org\/10.1097\/RLU.0b013e3182a757d3","journal-title":"Clin Nucl Med"},{"key":"5100_CR13","doi-asserted-by":"publisher","unstructured":"Ahlawat S, Fayad LM, Khan MS et al (2016) Current whole-body MRI applications in the neurofibromatosis: NF1, NF2, and schwannomatosis. Neurology 87. https:\/\/doi.org\/10.1212\/WNL.0000000000002929","DOI":"10.1212\/WNL.0000000000002929"},{"key":"5100_CR14","doi-asserted-by":"publisher","unstructured":"Ahlawat S, Baig A, Blakeley JO et al (2016) Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis. J Magn Reson Imaging 44. https:\/\/doi.org\/10.1002\/jmri.25236","DOI":"10.1002\/jmri.25236"},{"key":"5100_CR15","doi-asserted-by":"publisher","unstructured":"Ahlawat S, Blakeley JO, Rodriguez FJ, Fayad LM (2019) Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Neurology 93. https:\/\/doi.org\/10.1212\/WNL.0000000000008092","DOI":"10.1212\/WNL.0000000000008092"},{"key":"5100_CR16","doi-asserted-by":"publisher","unstructured":"Ahlawat S, Fayad LM (2018) Imaging cellularity in benign and malignant peripheral nerve sheath tumors: utility of the target sign by diffusion weighted imaging. Eur J Radiol 102. https:\/\/doi.org\/10.1016\/j.ejrad.2018.03.018","DOI":"10.1016\/j.ejrad.2018.03.018"},{"key":"5100_CR17","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3174\/ajnr.A3910","volume":"35","author":"S Demehri","year":"2014","unstructured":"Demehri S, Belzberg A, Blakeley J, Fayad LM (2014) Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience. AJNR Am J Neuroradiol 35:1615\u20131620. https:\/\/doi.org\/10.3174\/ajnr.A3910","journal-title":"AJNR Am J Neuroradiol"},{"key":"5100_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/135581969800300206","volume":"3","author":"C Jenkinson","year":"1998","unstructured":"Jenkinson C (1998) The SF-36 physical and mental health summary measures: an example of how to interpret scores. J Health Serv Res Policy 3:92\u201396. https:\/\/doi.org\/10.1177\/135581969800300206","journal-title":"J Health Serv Res Policy"},{"key":"5100_CR19","doi-asserted-by":"crossref","unstructured":"Dombi E (2013) Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology S33-40","DOI":"10.1212\/01.wnl.0000435744.57038.af"},{"key":"5100_CR20","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3171\/2020.3.JNS193230","volume":"134","author":"D Lewis","year":"2021","unstructured":"Lewis D, Donofrio CA, O\u2019Leary C et al (2021) The microenvironment in sporadic and neurofibromatosis type II-related vestibular Schwannoma: the same tumor or different? A comparative imaging and neuropathology study. J Neurosurg 134:1419\u20131429. https:\/\/doi.org\/10.3171\/2020.3.JNS193230","journal-title":"J Neurosurg"},{"key":"5100_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/neuonc\/noy177","volume":"21","author":"D Lewis","year":"2019","unstructured":"Lewis D, Roncaroli F, Agushi E et al (2019) Inflammation and vascular permeability correlate with growth in sporadic vestibular Schwannoma. Neuro Oncol 21:314\u2013325. https:\/\/doi.org\/10.1093\/neuonc\/noy177","journal-title":"Neuro Oncol"},{"key":"5100_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/MAO.0b013e31827c9fbf","volume":"34","author":"M de Vries","year":"2013","unstructured":"de Vries M, Briaire-de Bruijn I, Malessy MJA et al (2013) Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas. Otol Neurotol 34:347\u2013352. https:\/\/doi.org\/10.1097\/MAO.0b013e31827c9fbf","journal-title":"Otol Neurotol"},{"key":"5100_CR23","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1038\/s41467-025-57586-z","volume":"16","author":"AP Jones","year":"2025","unstructured":"Jones AP, Haley MJ, Meadows MH et al (2025) Spatial mapping of immune cell environments in NF2-related Schwannomatosis vestibular Schwannoma. Nat Commun 16:2944. https:\/\/doi.org\/10.1038\/s41467-025-57586-z","journal-title":"Nat Commun"},{"key":"5100_CR24","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/cam4.3767","volume":"10","author":"M Nishikawa","year":"2021","unstructured":"Nishikawa M, Inoue A, Ohnishi T et al (2021) CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma. Cancer Med 10:2013\u20132025. https:\/\/doi.org\/10.1002\/cam4.3767","journal-title":"Cancer Med"},{"key":"5100_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41467-023-40408-5","volume":"15","author":"SJ Liu","year":"2024","unstructured":"Liu SJ, Casey-Clyde T, Cho NW et al (2024) Epigenetic reprogramming shapes the cellular landscape of Schwannoma. Nat Commun 15:476. https:\/\/doi.org\/10.1038\/s41467-023-40408-5","journal-title":"Nat Commun"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05100-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05100-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05100-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:08:22Z","timestamp":1757185702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05100-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["5100"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05100-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Appropriate institutional review board approved the project and informed consent was obtained from the study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}